Ferring Pharmaceuticals

Privately held: no public share price

Assets

(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 3 of 3 assets
Target & Modality
Approved
Glucocorticoid receptorSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
AminosalicylateSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Phase 2
IL-6 transProtein / enzyme therapeutic
Inflammatory Bowel Disease
Ulcerative Colitis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

No financial reports recorded.